In chronic lymphocytic leukemia (CLL), the most prevalent lymphoid malignancy in western countries, patients have a median age at diagnosis of 72 years. In the last few years, there has been ...

Investigators found that lipid metabolism disruptions spark T-cell dysfunction in patients with chronic lymphocytic leukemia. Corresponding author Helga Simon-Molas, PhD, of the University of ...

Chronic lymphocytic leukemia-- or CLL-- is a type of cancer that happens in your blood and bone marrow, the spongy tissue inside your bones. While the exact cause isn't known, doctors do know that ...

Ibrutinib, a BTK inhibitor, is effective in treating relapsed CLL, with combination therapies improving response rates. Combination therapy with ibrutinib and venetoclax, guided by MRD ...